Baidu
map

MMWR Morb Mortal Wkly Rep:根据性取向和性别身份确定的COVID-19疫苗接种覆盖率和疫苗接种信心

2022-03-07 从医路漫漫 MedSci原创

与非同性恋人群相比,女同性恋、男同性恋、双性恋和跨性别者(LGBT)人群在与COVID-19严重疾病相关的健康状况方面的患病率更高,愿意信任和接受卫生保健服务。

  与非同性恋人群相比,女同性恋、男同性恋、双性恋和跨性别者(LGBT)人群在与COVID-19严重疾病相关的健康状况方面的患病率更高,愿意信任和接受卫生保健服务。关于LGBT人群COVID-19疫苗接种的数据有限,部分原因是在国家和州一级缺乏关于性取向和性别认同的常规数据收集。

  在2021年8月29日至10月30日期间,我们分析了来自全国免疫调查成人COVID-19模块(NIS-ACM)的数据,以评估18岁以上LGBT成年人的COVID-19疫苗接种覆盖率和对COVID-19疫苗的信心。根据性取向,男同性恋或女同性恋成人报告的疫苗接种率总体(85.4%)高于异性恋成人(76.3%)。按种族/民族划分,成年男同性恋或女同性恋非西班牙裔白人男性(94.1%)和女性(88.5%)以及西班牙裔男性(82.5%)报告的疫苗接种率高于非西班牙裔白人异性恋男性(74.2%)和女性(78。6%)。在非西班牙裔黑人成年人中,男同性恋或女同性恋女性(57.9%)和双性恋女性(62.1%)的疫苗接种率低于异性恋女性(75.6%)。在所有性取向和性别认同类别的非西班牙裔黑人LGBT人群中,疫苗接种覆盖率最低。在男同性恋或女同性恋成人和双性恋成人中,女性的疫苗接种率(分别为80.5%和74.2%)低于男性(分别为88.9%和81.7%)。根据性别认同,认为自己是跨性别者或非双性恋者的成年人接种疫苗的比例与认为自己不是跨性别者或非双性恋者的比例相近。

   在COVID-19疫苗的安全性和保护方面,男女同性恋和双性恋成年人比异性恋成年人更有治疗的信心,跨性别或非双性成年人比非跨性别成年人对COVID-19疫苗保护更有信心,为了预防严重疾病和死亡,所有美国人,包括同性恋、双性恋和变性者的人,都必须及时接种推荐的COVID-19疫苗。

表1 新冠肺炎接种状况和意图,按性别、性别认同、性取向和种族/民族分类-美国全国免疫调查成人COVID模块,2021年8月29日至10月30日

表2.2021年8月29日至10月30日美国新冠肺炎疫苗接种(≥1剂)覆盖面,按人口特征按性取向、性别认同和性别分层--美国全国免疫调查成人COVID模块

表3.按性取向和性别认同分列的新冠肺炎疫苗接种的行为和社会驱动因素--美国全国免疫调查成人COVID模块,2021年8月29日至10月30日

原文出处:McNaghten AD,  Brewer NT,  Hung MC,et al.COVID-19 Vaccination Coverage and Vaccine Confidence by Sexual Orientation and Gender Identity - United States, August 29-October 30, 2021.MMWR Morb Mortal Wkly Rep 2022 Feb 04;71(5) 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038128, encodeId=21d8203812809, content=<a href='/topic/show?id=d26690569a5' target=_blank style='color:#2F92EE;'>#覆盖率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90569, encryptionId=d26690569a5, topicName=覆盖率)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Mar 21 11:08:21 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200155, encodeId=0743120015544, content=学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Mon Mar 07 09:15:49 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258145, encodeId=73e61258145df, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Feb 26 04:08:21 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377490, encodeId=ce6f13e7490bb, content=<a href='/topic/show?id=58b452660d9' target=_blank style='color:#2F92EE;'>#性取向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52660, encryptionId=58b452660d9, topicName=性取向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sat Feb 26 04:08:21 CST 2022, time=2022-02-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038128, encodeId=21d8203812809, content=<a href='/topic/show?id=d26690569a5' target=_blank style='color:#2F92EE;'>#覆盖率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90569, encryptionId=d26690569a5, topicName=覆盖率)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Mar 21 11:08:21 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200155, encodeId=0743120015544, content=学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Mon Mar 07 09:15:49 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258145, encodeId=73e61258145df, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Feb 26 04:08:21 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377490, encodeId=ce6f13e7490bb, content=<a href='/topic/show?id=58b452660d9' target=_blank style='color:#2F92EE;'>#性取向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52660, encryptionId=58b452660d9, topicName=性取向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sat Feb 26 04:08:21 CST 2022, time=2022-02-26, status=1, ipAttribution=)]
    2022-03-07 xulv123

    学习~

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2038128, encodeId=21d8203812809, content=<a href='/topic/show?id=d26690569a5' target=_blank style='color:#2F92EE;'>#覆盖率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90569, encryptionId=d26690569a5, topicName=覆盖率)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Mar 21 11:08:21 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200155, encodeId=0743120015544, content=学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Mon Mar 07 09:15:49 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258145, encodeId=73e61258145df, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Feb 26 04:08:21 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377490, encodeId=ce6f13e7490bb, content=<a href='/topic/show?id=58b452660d9' target=_blank style='color:#2F92EE;'>#性取向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52660, encryptionId=58b452660d9, topicName=性取向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sat Feb 26 04:08:21 CST 2022, time=2022-02-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038128, encodeId=21d8203812809, content=<a href='/topic/show?id=d26690569a5' target=_blank style='color:#2F92EE;'>#覆盖率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90569, encryptionId=d26690569a5, topicName=覆盖率)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Mar 21 11:08:21 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200155, encodeId=0743120015544, content=学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Mon Mar 07 09:15:49 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258145, encodeId=73e61258145df, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Feb 26 04:08:21 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377490, encodeId=ce6f13e7490bb, content=<a href='/topic/show?id=58b452660d9' target=_blank style='color:#2F92EE;'>#性取向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52660, encryptionId=58b452660d9, topicName=性取向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a410, createdName=zxxiang, createdTime=Sat Feb 26 04:08:21 CST 2022, time=2022-02-26, status=1, ipAttribution=)]
    2022-02-26 zxxiang

相关资讯

Eur Respir J:COVID-19纵隔气肿:严重COVID-19肺炎的一种表现?

纵隔气肿(PTM)是纵膈腔内空气或气体的异常存在。自发性PTM很少见,在33000例住院患者中约有1例出现。

Infection:耐多药鲍曼不动杆菌感染对重症监护病房住院的 COVID-19 患者的预后的影响

新冠肺炎一般指新型冠状病毒肺炎。 新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19),简称“新冠肺炎”,世界卫生组织命名为“2019冠状病毒病。

Nat Commun:一项关于英国1260万成年人的肥胖、种族和COVID-19死亡率的队列研究

肥胖已经成为国际上导致2019年新冠肺炎(Coronavirus Disease 2019年)严重程度和死亡率的最典型的风险因素之一,在社区和住院环境中都是如此。

Front Immunol :COVID-19患者的维生素D状况和炎症反应之间的联系

2020年以来,由新型β型冠状病毒SARS-CoV-2引起的冠状病毒疾病2019 (COVID-19)作为一种大流行出现传播,表现出从无症状到致命的严重急性呼吸综合征(SARS-CoV)的可变表型

IJNS:医务人员感染COVID-19以护士和女性居多,感染后总死亡率为9/1000

COVID-19大流行影响了医务人员的身心健康问题,需要有针对性的干预措施和卫生政策来支持世界各地的医疗工作者。

Baidu
map
Baidu
map
Baidu
map